Delivering tumor-specific genes is used to arm iNKT cells, converting them into highly active, universal anti-cancer effectors capable of dual recognition. This strategy minimizes antigen escape by leveraging both the engineered receptor and the endogenous CD1d-restricted TCR.
Targeted Drug Delivery for iNKT Cell Therapy
Invariant natural killer T (iNKT) cells are potent immune regulators that rapidly trigger cytotoxicity and cytokine release upon recognizing lipid antigens. iNKT therapy offers universal (non-HLA restricted), rapid, and dual immunomodulatory potential for oncology and autoimmune diseases. Creative Biolabs specializes in targeted delivery technology to overcome cell rarity, in vitro expansion, and gene modification bottlenecks, unlocking unique therapeutic advantages.
What is Targeted Delivery?
In iNKT cell therapy, targeted delivery defines the efficient, low-toxicity introduction of specific genetic material, such as TCR genes, directly into iNKT cells ex vivo. The strategy focuses on two critical outcomes. First is maximizing efficiency, utilizing state-of-the-art non-viral transfection protocols for these rare cell types to ensure limited primary cells are fully leveraged. Second is ensuring functional integrity, guaranteeing the delivery process does not impair the intrinsic CD1d recognition capability, the natural cytokine secretion profile (Th1 bias), or the potent cytotoxic function of the resulting engineered iNKT product.
Applications for INKT Cell Therapy
Enhanced Tumor Cell Therapy
Autoimmune and Inflammatory Diseases
The universal nature of iNKT cells enables the delivery of immunomodulatory molecules or specific cytokine mRNAs to precisely regulate their activation state. This approach aims to achieve immune balance by suppressing detrimental Th1 responses or promoting regulatory IL-10 secretion.
iNKT Cell Expansion and Activation
Delivery systems can introduce proliferative and anti-apoptotic genes (such as IL-15 or IL-21 genes) to significantly increase the in vitro expansion rate and enhance the in vivo persistence of adoptively transferred iNKT cells, creating a more durable therapy.
Fig.1 The anti-tumour mechanisms of iNKT cells.1
Delivery Challenges of INKT Cell Therapy
Cell Rarity & Difficulty in Modification In vitro Expansion Efficiency & Cost Post-Transduction Functional Integrity
iNKT cells are inherently low in abundance in peripheral blood, and their unique physiology results in low transfection efficiency with most conventional gene modification vectors. This challenge makes it difficult to obtain sufficient, functionally enhanced therapeutic doses.
What We Can Offer
Creative Biolabs offers professional targeted delivery technologies, focusing on solving the challenges of rarity, efficiency, and functional integrity in iNKT therapy manufacturing:
Efficient Transfection of Rare Cells
We provide optimized LNP/nanogel platforms and customized transfection protocols tailored specifically to the characteristics of iNKT cells. This ensures the highest delivery efficiency with minimal cytotoxicity or cell damage, maximizing yields from rare primary cell starting material.
Function-Enhancing Molecular Delivery
We enable the co-delivery of cytokine genes, such as IL-15 or IL-21 mRNA, which promote iNKT cell proliferation and survival. This significantly increases in vitro expansion rates and drives the generation of CD62L+ subsets associated with superior in vivo persistence and efficacy.
Universal iNKT Platform Support
Our scalable, non-viral delivery solutions support the rapid, cost-effective engineering of iPSC-induced iNKT or other derived cells, accelerating the development of truly universal therapeutic products.
Functional Characterization & Optimization
We provide specialized assessment services for key metrics, including the iNKT cytokine secretion profile, CD1d recognition ability, and in vitro killing activity of transfected cells, guaranteeing functional integrity and enhanced efficacy.
Why Choose Us?
Scientific Precision
Our protocols are informed by an understanding of iNKT subset heterogeneity, targeting the potent CD4- Th1 population for engineering.
Non-Viral Excellence
We minimize genotoxicity and maximize translational speed using proprietary non-viral delivery systems.
Efficacy Enhancement
We go beyond modification by co-delivering IL-15 or IL-21 to boost in vivo persistence and proliferation.
Regulatory Ready
Our scalable processes are designed to meet clinical manufacturing standards and lower the cost of goods for universal iNKT therapies.
Workflow
Your iNKT therapy requires overcoming the challenge of cell rarity and modification efficiency. Please contact our team of iNKT delivery experts for a customized, non-viral engineering solution that can accelerate your pipeline.
Reference
- Look, Alex, et al. "Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes." Frontiers in Immunology 14 (2023): 1176724. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1176724.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
